Comparative Pharmacology
Head-to-head clinical analysis: CURRETAB versus NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CURRETAB versus NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE.
CURRETAB vs NORETHINDRONE AND ETHINYL ESTRADIOL AND FERROUS FUMARATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Progesterone receptor agonist; induces secretory changes in endometrium, inhibits pituitary gonadotropin secretion, and has anti-estrogenic effects.
Norethindrone is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining. Ferrous fumarate is an iron supplement for replacement of menstrual iron loss.
5 mg orally once daily for 10 consecutive days per cycle, beginning on day 16 of the menstrual cycle.
One tablet (norethindrone 1 mg, ethinyl estradiol 10 mcg, and ferrous fumarate 75 mg) orally once daily at the same time each day for 28 consecutive days, starting on day 1 of menstrual cycle.
None Documented
None Documented
Terminal elimination half-life of medroxyprogesterone acetate (MPA) is approximately 12-17 hours (mean ~14 h) for oral administration; with intramuscular depot, half-life extends to ~6-7 weeks due to slow absorption from injection site
Norethindrone: 5-8 hours (terminal). Ethinyl estradiol: 13-27 hours (terminal). Clinical context: dosing interval is 24 hours based on ethinyl estradiol half-life.
Primarily renal (60-70% as metabolites, <10% unchanged); biliary/fecal (20-30%)
Norethindrone: ~80% renal (as glucuronide and sulfate conjugates), ~20% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal via enterohepatic recirculation. Ferrous fumarate: iron is absorbed and incorporated; excess excreted in feces as unabsorbed.
Category C
Category D/X
Progestin
Progestin